CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial

CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial

Abstract Background Oral CXC chemokine receptor 2 (CXCR2) antagonists have been shown to inhibit neutrophil migration and activation in the lung in preclinical and human models of neutrophilic airway inflammation. A previous study with danirixin, a reversible CXCR2 antagonist, demonstrated a trend f...

Full description

Bibliographic Details
Main Authors: Aili L. Lazaar, Bruce E. Miller, Alison C. Donald, Thomas Keeley, Claire Ambery, John Russell, Henrik Watz, Ruth Tal-Singer, for 205724 Investigators
Format: Article
Language:English
Published: BMC 2020-06-01
Series:Respiratory Research
Subjects:
COPD
Clinical trial
Danirixin
CXCR2
Online Access:http://link.springer.com/article/10.1186/s12931-020-01401-4

Internet

http://link.springer.com/article/10.1186/s12931-020-01401-4

Similar Items